Aluminium hydroxide

CLINICAL USE

  • Phosphate binding agent
  • Antacid

    DOSE IN NORMAL RENAL FUNCTION

  • Phosphate binder: 4–20 capsules daily individed doses
  • Antacid: 1 capsule 4 times daily and atbedtime

    PHARMACOKINETICS

  • Molecular weight                           :
    78
  • %Protein binding                           :
    70–90
  • %Excreted unchanged in urine     :
    No data
  • Volume of distribution (L/kg)       :
    No data
  • half-life – normal/ESRD (hrs)      :
    No data

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           :
    Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :
    Unknown dialysability. Dose as in
    normal renal function
  • HD                     :
    Unknown dialysability. Dose as in
    normal renal function
  • HDF/high flux   :
    Unknown dialysability. Dose as in
    normal renal function
  • CAV/VVHD      :
    Unknown dialysability. Dose as in
    normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
    None known

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

  • K/DOQI guidelines caution that CKD 5patients on chronic therapy may develop
    aluminium toxicity; therefore best avoided
    in all but short-term therapy (calcium
    carbonate, calcium acetate, lanthanum or
    sevelamer are used in chronic therapy)
  • Take/administer with or immediatelybefore meals
  • In patients undergoing chronic therapywith aluminium hydroxide, serum
    aluminium levels should be monitored
    • Tags:

    Related News

    ffddfd

    Hyperlipidemia